Clinical Trials Logo

Follicular Lymphoma clinical trials

View clinical trials related to Follicular Lymphoma.

Filter by:

NCT ID: NCT03814785 Completed - Follicular Lymphoma Clinical Trials

GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL)

ASSIST_FL
Start date: December 1, 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate comparability of the ORR in patients with previously untreated, advanced stage FL who receive GP2013-treatment to patients who receive MabThera-treatment.

NCT ID: NCT03806179 Completed - Follicular Lymphoma Clinical Trials

Study of Safety and Efficacy of Betalutin and Rituximab in Patients With FL

LYMRIT-37-07
Start date: October 4, 2018
Phase: Phase 1
Study type: Interventional

This study is a Phase 1b, open-label, single arm dose escalation study of Betalutin followed by rituximab in patients with previously treated follicular lymphoma. The purpose of this study is to characterise the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumour activity of Betalutin in combination with rituximab.

NCT ID: NCT03610061 Completed - Follicular Lymphoma Clinical Trials

A Trial of Radiotherapy and Durvalumab in DLBCL and FL

RaDD
Start date: November 1, 2018
Phase: Phase 1
Study type: Interventional

The primary objective for this study is to determine the safety profile of radiotherapy and durvalumab, a PD-L1 inhibitor. Primary endpoint: Toxicity, drug pharmacokinetics (PK), maximum tolerated dose (MTD) and recommended phase two dose (RPTD) of simultaneous radiotherapy plus durvalumab in patients with relapsed or refractory DLBCL or FL. Secondary endpoints: - ORR - Progression-free survival - Overall survival Exploratory endpoints include description of biological effects of combination radiotherapy plus durvalumab (Imaging results, immune function, PK and PD-see 'research methodologies') and in the PET-Sub-Study, biodistribution of 89Zr Durvalumab and 89Zr-IAB22M2C.

NCT ID: NCT03525665 Completed - Follicular Lymphoma Clinical Trials

Study on the Role of FDG-PET in Patients With FL at Time of Relapse/Progression

Start date: May 2016
Phase:
Study type: Observational

The study is designed as a retrospective analysis of patients with relapsed/refractory FL identified by the hematological centers of Italy.

NCT ID: NCT03520920 Completed - Follicular Lymphoma Clinical Trials

BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)

Start date: January 4, 2018
Phase: Phase 2
Study type: Interventional

This was a multicenter, open-label, phase 2 study to evaluate efficacy, safety, and tolerability of BGB-3111 (zanubrutinib) 160 milligrams (mg) twice daily (BID) in combination with rituximab in Chinese participants with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) (non-GCB [non-germinal center B-cell-like] subtype) and R/R indolent lymphoma (follicular lymphoma [FL] and marginal zone lymphoma [MZL]).

NCT ID: NCT03424603 Completed - Multiple Myeloma Clinical Trials

Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies

Start date: February 22, 2018
Phase: Phase 1
Study type: Interventional

First-in-human Phase 1 trial to study the safety, pharmacokinetics and preliminary efficacy of STRO-001 given intravenously every 3 weeks.

NCT ID: NCT03381768 Completed - Follicular Lymphoma Clinical Trials

Peptide Vaccination Against PD-L1 and PD-L2 in Relapsed Follicular Lymphoma

Start date: December 12, 2017
Phase: Phase 1
Study type: Interventional

An open phase-1, first-in-human, clinical trial investigating the safety and immunological effects of peptide vaccination with Programmed Death Ligand 1 and 2 (PD-L1 and PD-L2) peptides in patients with relapsed follicular lymphoma.

NCT ID: NCT03374137 Completed - Clinical trials for Chronic Lymphocytic Leukemia

Observational Study to Monitor Safety and Effectiveness of Obinutuzumab in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia

Start date: March 9, 2018
Phase:
Study type: Observational

This study aims to collect clinical data, mainly focused on safety, in the local target population as per the requirement of Korea Ministry of Food and Drug Safety for market authorization. The study population comprises patients with approved local indications chronic lymphocytic leukemia (CLL) and/or follicular lymphoma (FL) in routine clinical practice after launch.

NCT ID: NCT03329950 Completed - Breast Cancer Clinical Trials

A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies

Start date: December 1, 2017
Phase: Phase 1
Study type: Interventional

This is a study to determine the maximum tolerated dose (MTD) for CDX-1140 (CD40 antibody), either alone or in combination with CDX-301 (FLT3L), pembrolizumab, or chemotherapy and to further evaluate its tolerability and efficacy in expansion cohorts once the MTD is determined.

NCT ID: NCT03297424 Completed - Solid Tumor Clinical Trials

A Study of PLX2853 in Advanced Malignancies.

Start date: September 12, 2017
Phase: Phase 1
Study type: Interventional

The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in subjects with advanced malignancies.